反-1,3-环己烷二胺 | 26772-34-9

• 物质功能分类: 生物化工 - 生化试剂 - 胺、酸和盐
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 反-1,3-环己烷二胺
• 中文别名: 反-1,3-二氨基环己烷
• 英文名称: (1R,3S)-cyclohexane-1,3-diamine
• 英文别名: cis-1,3-diaminocyclohexane；cis-1.3-Diamino-cyclohexan；cis-cyclohexane-1,3-diamine；cis-1,3-Cyclohexanediamine
• CAS: 26772-34-9
• 化学式: C₆H₁₄N₂
• 分子量: 114.191
• InChiKey: GEQHKFFSPGPGLN-OLQVQODUSA-N

物化性质

• 沸点：
  198°C(lit.)
• 密度：
  0.9515 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 海关编码：
  2921300090
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  反-1,3-环己烷二胺 在 盐酸 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  Serendipity in drug-discovery: A new series of 2-(benzyloxy)benzamides as TRPM8 antagonists

  摘要：

  A new series of 2-(benzyloxy) benzamides are presented that are potent functional antagonists of TRPM8 and possess improved LipE and LE compared to the original lead. They were discovered through a series of compound libraries and we present a powerful visualization method for the chemical space explored with each library. Remarkably this new series originated from the highest risk design strategy where compounds were synthesised with the least degree of similarity to the lead structure. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.016
• 作为产物：
  描述：

  N-[(1R,3S)-3-乙酰氨基环己基]乙酰胺 在 盐酸 作用下， 反应 12.0h， 以67%的产率得到反-1,3-环己烷二胺
  参考文献：
  名称：

  Insights into the van der Waals Radius of Low-Spin Ni(ii) fromMolecular Mechanics Studies and the Crystal Structures of [Ni(cis-cyclohexane-1,3-diamine)2]Cl2, [Ni{(R)-5,5,7-trimethyl-1,4-diazacycloheptane}2]Cl2·H2O and [Ni(5,7-dimethyl-1,4-diazacycloheptane)2](ClO4)2. Synthesis of 5,7-Dimethyl-1,4-diazacycloheptane and an Improved Synthesis of cis-Cyclohexane-1,3-diamine

  摘要：

  本文描述了三种双（二胺）镍（II）配合物的结构，选择这些配合物是为了揭示镍（II）的范德华半径。[Ni(cis-1,3-chxn)2]Cl2（cis-1,3-chxn = cis-cyclohexane-1,3-diamine）在单斜空间群 P21/n 中结晶，a 为 6.397(2)，b 为 16.463(4)，c 为 7.229(2)埃，b 为 90.70(2)。[Ni{(R)-tmdz}2]Cl2�H2O（tmdz = 5,5,7-三甲基-1,4-二氮杂环庚烷）在正交空间群 P212121 中结晶，a 为 10.678(1)埃，b 为 11.073(5)埃，c 为 17.968(6)埃。[Ni(dmdz)2](ClO4)2（dmdz = 5,7-二甲基-1,4-二氮环庚烷）在单斜空间群 P21/n 中结晶，a 9.582(1)，b 10.390(2)，c 11.817(3)埃，β 96.19(2)。在所有这三种结构中，都观察到了短的 Ni�H 和 Ni�C 相互作用，范围分别为 2.37 至 2.61 Å 和 2.99 至 3.03 Å。利用分子力学模型重现这些分离，我们得出低自旋镍(ii)的范德华半径为 1.35 Å。对固态镍�O接触的分析结果表明，范德华半径约为 1.26 Å，这与分子力学得出的数值一致，因为后者通常更长。

  DOI：

  10.1071/ch02099

文献信息

• INHIBITORS OF INFLUENZA VIRUSES REPLICATION
  申请人：Charifson Paul S.

  公开号：US20120171245A1

  公开（公告）日：2012-07-05

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒的复制、减少生物样本或患者中流感病毒量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的由结构公式（I）表示的化合物： 或其药用可接受盐，其中结构公式（IA）的值如本文所述。由结构公式（IA）或其药用可接受盐表示的化合物，其中结构公式（IA）的值如本文所述。药物组合物包括有效量的上述化合物或其药用可接受盐，以及药用可接受载体、佐剂或车辆。
• [EN] MCHIR ANTAGONISTS<br/>[FR] ANTAGONISTES DU MCH1R
  申请人：ASTRAZENECA AB

  公开号：WO2004004726A1

  公开（公告）日：2004-01-15

  The present invention provides compounds of formula (I), wherein R1 represents a C1-4alkoxy group optionally substituted by one or more fluoro or a C1-4alkyl group optionally substituted by one or more fluoro; n represents 0 or 1; R2 represents a C1-4alkyl group optionally substituted by one or more fluoro or a C1-4alkoxy group optionally substituted by one or more fluoro; m represents 0 or 1; R3 represents H or a C1-4alkyl group; L1 represents an alkylene chain (CH2)r in which r represents 2 or 3 or L1 represents a cyclohexyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L1 represents a cyclopentyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group and additionally when R5 represents 9, 10-methanoanthracen-9(10H)-yl the group -L1-N(R4)- together represents a piperidyl ring which is linked to L2 through the piperidinyl nitrogen and to N-R3 via the 4 position of the piperidyl ring with the proviso that when R5 represents 9, 10-methanoanthracen-9(10H)-yl then r is only 2; R4 represents H or a C1-4alkyl group optionally substituted by one or more of the following: an aryl group or a heteroaryl group; L2 represents a bond or an alkylene chain (CH2)s in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C1-4alkyl group, phenyl or heteroaryl; R5 represents aryl, a heterocyclic group or a C3-8cycloalkyl group which is optionally fused to a phenyl or to a heteroaryl group; as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof; with provisos, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheier's disease and pain related disorders and to pharmaceutical compositions containing them.

  本发明提供了以下式（I）的化合物，其中R1代表一个C1-4烷氧基团，该基团可以选择地被一个或多个氟或一个C1-4烷基基团选择性地取代；n代表0或1；R2代表一个C1-4烷基基团，该基团可以选择地被一个或多个氟或一个C1-4烷氧基团选择性地取代；m代表0或1；R3代表H或一个C1-4烷基基团；L1代表一个烷基链（CH2）r，其中r代表2或3，或者L1代表一个环己基团，其中分别带有R3和R4的两个氮原子通过环己基团的1,3位或1,4位连接到环己基团，或者L1代表一个环戊基团，其中分别带有R3和R4的两个氮原子通过环戊基团的1,3位连接到环戊基团，另外当R5代表9,10-甲基蒽-9(10H)-基时，-L1-N(R4)-群共同代表一个通过哌啶环与L2通过哌啶氮连接并通过哌啶环的4位与N-R3连接的哌啶环，但当R5代表9,10-甲基蒽-9(10H)-基时，r仅为2；R4代表H或一个C1-4烷基基团，该基团可以选择地被以下之一或多个取代：芳基或杂芳基；L2代表一个键或一个烷基链（CH2）s，其中s代表1,2或3，其中该烷基链可以选择地被以下之一或多个取代：一个C1-4烷基基团，苯基或杂芳基；R5代表芳基，一个杂环基团或一个C3-8环烷基基团，该基团可以选择地与苯基或杂芳基融合；以及它们的光学异构体和拉氏体，以及其药学上可接受的盐；具有特定条件，制备这种化合物的方法，它们在治疗肥胖症、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫、以及相关疾病，以及神经系统疾病如痴呆症、多发性硬化症、帕金森病、亨廷顿舞蹈症、阿尔茨海默病和与疼痛相关的疾病的治疗中的用途，以及含有它们的药物组合物。
• Cobalt-based molecular electrocatalysis of nitrile reduction: evolving sustainability beyond hydrogen
  作者：Simon N. Child、Radoslav Raychev、Nathan Moss、Benjamin Howchen、Peter N. Horton、Christopher C. Prior、Vasily S. Oganesyan、John Fielden

  DOI：10.1039/c9dt00773c

  日期：——

  Two complexes, designed as hydrogen evolution catalysts, are shown to be the first earth-abundant molecular electrocatalysts for reduction of acetonitrile to ethylamine.

  两种设计为氢进化催化剂的复合物被证明是第一批用于将乙腈还原为乙胺的丰富地球元素分子电催化剂。
• [EN] THERAPEUTIC AGENTS I<br/>[FR] AGENTS THERAPEUTIQUES I
  申请人：ASTRAZENECA AB

  公开号：WO2005066132A1

  公开（公告）日：2005-07-21

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的化学式(I)，制备这种化合物的方法，它们在治疗肥胖、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫以及相关疾病，以及神经系统疾病如痴呆症、多发性硬化症、帕金森病、亨廷顿舞蹈症、阿尔茨海默病和与疼痛相关的疾病中的应用，以及含有它们的药物组合物。
• Ligand‐Enabled Nickel‐Catalyzed Redox‐Relay Migratory Hydroarylation of Alkenes with Arylborons
  作者：Yuli He、Chuang Liu、Lei Yu、Shaolin Zhu

  DOI：10.1002/anie.202001742

  日期：2020.6.2

  A redox-relay migratory hydroarylation of isomeric mixtures of olefins with arylboronic acids catalyzed by nickel complexes bearing diamine ligands is described. A range of structurally diverse 1,1-diarylalkanes, including those containing a 1,1-diarylated quaternary carbon, were obtained in excellent yields and with high regioselectivity. Preliminary experimental evidence supports the proposed non-dissociated

  描述了由带有二胺配体的镍配合物催化的烯烃与芳基硼酸的异构体混合物的氧化还原-中继迁移氢化芳基化。以优异的产率和高区域选择性获得了一系列结构多样的1，1-二芳基烷烃，包括那些含有1，1-二芳基化季碳的烷烃。初步的实验证据支持了在苄基位置进行选择性还原消除之前，芳烃-镍（II）-氢化物物种沿着烯烃的烷基链的非离解链走动。证明低至0.5mol％的催化剂负载量对于大规模合成是足够的，同时保持高反应性，突出了该转化的实用价值。